DSM - Repurchase and cancellation of shares (week 46)
Royal DSM N.V. has repurchased 933,109 of its own shares in the
period from 8 November 2007 up to and including 14 November 2007 at
an average price of EUR 36.11. This is in accordance with the first
phase of the share buyback program, announced on 1 October 2007. The
consideration of this repurchase was EUR 33.7 million.
The total number of shares repurchased under the first phase of this
program to date is 4,138,096 shares for a total consideration of EUR
158.5 million.
In accordance with the cancellation process initiated on 13 September
2007, Royal DSM N.V. announces that 7,128,008 shares, bought during
the second phase of the during September completed share buyback
program, have been cancelled as per 13 November 2007. As a result the
number of issued ordinary shares has decreased by 3.8% to
181,425,000.
DSM
DSM creates innovative products and services in life sciences and
materials sciences, contributing to the quality of life. DSM's
products and services are used globally in a wide range of markets
and applications, supporting a healthier, more sustainable and
enjoyable way of living. End markets include human and animal
nutrition and health, personal care, pharmaceuticals, automotive,
coatings and paint, electrics & electronics, life protection and
housing. The company strategy, Vision 2010 - Building on Strengths,
focuses on accelerating profitable and innovative growth of the
company's specialties portfolio. The key drivers of this strategy are
market-driven growth and innovation, an increased presence in
emerging economies and operational excellence. DSM has annual sales
of almost EUR 9 billion and employs some 22,000 people worldwide. The
company is headquartered in the Netherlands, with locations in
Europe, Asia, the Americas, Africa and Australia. More information on
DSM can be found at www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Elvira Luykx
tel. +31 (0) 45 tel. +31 (0) 45 5782864
5782035 fax +31 (0) 45 5782595
fax +31 (0) 45 e-mail
5740680 investor.relations@dsm.com
e-mail media.relations@dsm.com
